We discovered defective bone marrow B-lymphopoiesis with reduced B-cell output in AAV, present already before rituximab treatment. Reduced commitment into the B-cell lineage is not due to an intrinsic ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Zenas’ lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcγRIIb, which are broadly present across B cell lineage, to inhibit the activity of ...

The chimeric fusion oncogene early B-cell factor 1–platelet-derived growth ... EBF1 is a nuclear transcription factor required for normal B-lineage specification, commitment and development.

The firm is also shuttering its allogeneic cell therapy platform and has tasked a new CEO to lead the company through a merger.

Since several memory B-cell subsets have distinct roles during the immune response ... A/Cambodia/e0826360/2020 - H3N2; B/Washington/02/2019 - B/Victoria lineage; B/Phuket/3073/2013 - B/Yamagata ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

What Is B-Cell Lymphoma? B-cell lymphoma is a cancer that forms in your white blood cells called lymphocytes. These cells are made by your lymphatic system, which plays an important role in immunity.

About NRX-0305 NRX-0305 is a potent, selective, and orally bioavailable mutant-specific BRAF degrader that Nurix is exploring for use in oncology. Nurix has reported preclinical data demonstrating ...

Nurix’s wholly owned pipeline comprises targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, an E3 ligase ...